Oncology & Cancer

Calquence approved to treat CLL, SLL

(HealthDay)—The U.S. Food and Drug Administration has granted supplemental approval to Calquence (acalabrutinib) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the agency announced ...

page 1 from 5